Finally, tepotinib has demonstrated promising activity in patients with HCC with MET overexpression who were either systemic treatment-naïve (NCT01988493; ref. 67) or previously treated with sorafenib (NCT02115373; ref. 68). Here, MET is linked to hepatocellular carcinoma.